Výsledky vyhledávání - "Julia Eismann"

Akademický článek

Single Nucleotide Polymorphism-Based Real-Time PCR Screening Assay for Rapid Tracking of Bacterial Infection Clusters To Complement Whole-Genome Sequencing Efforts during Outbreak Investigations

Autor: Janina Treffon, Bianca Heppner, Julia Eismann, Julia Bothe, Birgit Omengo, Alexander Mellmann

Publikováno v: Microbiology Spectrum, Vol 10, Iss 6 (2022)

ABSTRACT Infection clusters of multidrug-resistant bacteria increase mortality and entail expensive infection control measures. Whereas whole-genome sequencing (WGS) is the current gold standard to confirm infection clusters, PCR-based assays targeti

Externí odkaz: https://doaj.org/article/583df339913544caa09b90a4516a26c9

Zobrazit plný text záznamu

Akademický článek

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers

Autor: Ewa Przybytkowski, Thomas Davis, Abdelrahman Hosny, Julia Eismann, Ursula A. Matulonis, Gerburg M. Wulf, Sheida Nabavi

Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-16 (2020)

Abstract Background BRCA1/2 germline mutation related cancers are candidates for new immune therapeutic interventions. This study was a hypothesis generating exploration of genomic data collected at diagnosis for 19 patients. The prominent tumor muta

Externí odkaz: https://doaj.org/article/995b17e12f284b2aba40fbf5e46134e0

Zobrazit plný text záznamu

Plný text ve formátu HTML

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

Autor: Felipe Batalini, Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley, Geoffrey I. Shapiro, Viktor Adalsteinsson, Eric P. Winer, Panagiotis A. Konstantinopoulos, Alan D'Andrea, Elizabeth M. Swisher, Ursula A. Matulonis, Gerburg M. Wulf, Erica L. Mayer

Publikováno v: Clin Cancer Res

Purpose: We had previously reported on the safety and the recommended phase 2 dose (RP2D) of olaparib in combination with the PI3Kα-specific inhibitor alpelisib in patients with high-grade serous ovarian cancer as studied in a phase 1b trial (NCT016

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ae477324d8cfdc088b8fee2cf6d1473
https://doi.org/10.1158/1078-0432.ccr-21-3045

Zobrazit plný text záznamu

Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib

Autor: Sheida Nabavi, Panagiotis A. Konstantinopoulos, Charles J. Murphy, Gerburg M. Wulf, Julia Eismann, Ioannis S. Vlachos, Ursula A. Matulonis, Yujing J. Heng, Kathryn P. Gray, Johannes M. Waldschmidt

Publikováno v: Journal of Cancer Research and Clinical Oncology

Purpose Fusion genes can be therapeutically relevant if they result in constitutive activation of oncogenes or repression of tumor suppressors. However, the prevalence and role of fusion genes in female cancers remain largely unexplored. Here, we inv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffd57f6827ea0e6df17a29a9abf793c7
https://doi.org/10.1007/s00432-019-03078-9

Zobrazit plný text záznamu

Abstract IA23: PI3K inhibitors as a backbone for combination treatments for breast and ovarian cancer

Autor: Julia Eismann, Gerburg M. Wulf, Bose Kucherlapati, Olmo Sonzongi, Ursula A. Matulonis, Panos Konstantinopoulos, William T. Barry

Publikováno v: Molecular Cancer Research. 18:IA23-IA23

PI3K inhibitors reduce glucose uptake and utilization by tumors. Yet in solid tumor clinical trials the efficacy of PI3K -inhibitors as single agents has been limited. Therefore, we have focused on harnessing the antimetabolic efficacy of PI3K inhibi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75dd3da004f30c4712a340b22aa16a10
https://doi.org/10.1158/1557-3125.pi3k-mtor18-ia23

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání